Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine

The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.

Study Overview

• Status: Completed
• Conditions: Meningitis, Meningococcal
• Intervention / Treatment: Combination product: MenABCWY vaccine; Combination product: Placebo; Biological: MenACWY vaccine; Combination product: MenB vaccine

• Study Type: Interventional
• Enrollment (Actual): 1250
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, 1426
    • GSK Investigational Site
  • Ciudad Autonoma de Buenos Aires, Argentina, C1428
    • GSK Investigational Site
  • Cordoba, Argentina, 5000
    • GSK Investigational Site
  • Rio Cuarto, Argentina, 5800
    • GSK Investigational Site
  • Buenos Aires
    • Caba, Buenos Aires, Argentina, C1222
      • GSK Investigational Site
    • Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina, C1425AWK
      • GSK Investigational Site
    • Mar del Plata, Buenos Aires, Argentina, B7600FYH
      • GSK Investigational Site
  • Tucumán
    • San Miguel de Tucuman, Tucumán, Argentina, T4000NWB
      • GSK Investigational Site
    • San Miguel de Tucumán, Tucumán, Argentina, T4000IHE
      • GSK Investigational Site
• Australia
  • New South Wales
    • Coffs Harbour, New South Wales, Australia, 2450
      • GSK Investigational Site
    • Darlinghurst, New South Wales, Australia, 2010
      • GSK Investigational Site
    • Kanwal, New South Wales, Australia, 2259
      • GSK Investigational Site
    • Maroubra, New South Wales, Australia, 2035
      • GSK Investigational Site
  • Queensland
    • Taringa, Queensland, Australia, 4068
      • GSK Investigational Site
    • Tarragindi, Queensland, Australia, 4121
      • GSK Investigational Site
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • GSK Investigational Site
    • Parkville, Victoria, Australia, 3052
      • GSK Investigational Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • GSK Investigational Site
• Canada
  • Ontario
    • Guelph, Ontario, Canada, N1H 1B1
      • GSK Investigational Site
    • Sarnia, Ontario, Canada, N7T 4X3
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M9V 4B4
      • GSK Investigational Site
• United States
  • Arkansas
    • Jonesboro, Arkansas, United States, 72401
      • GSK Investigational Site
  • California
    • Banning, California, United States, 92220
      • GSK Investigational Site
    • Chula Vista, California, United States, 91911
      • GSK Investigational Site
    • West Covina, California, United States, 91790
      • GSK Investigational Site
  • District of Columbia
    • Washington, District of Columbia, United States, 20017
      • GSK Investigational Site
  • Florida
    • Miami, Florida, United States, 33126
      • GSK Investigational Site
    • Miami, Florida, United States, 33135
      • GSK Investigational Site
    • Port Orange, Florida, United States, 32127
      • GSK Investigational Site
  • Georgia
    • Atlanta, Georgia, United States, 30338
      • GSK Investigational Site
    • Columbus, Georgia, United States, 31904
      • GSK Investigational Site
    • Sandy Springs, Georgia, United States, 30328
      • GSK Investigational Site
  • Idaho
    • Meridian, Idaho, United States, 83642
      • GSK Investigational Site
  • Illinois
    • Champaign, Illinois, United States, 61822
      • GSK Investigational Site
    • Quincy, Illinois, United States, 62301
      • GSK Investigational Site
  • Kentucky
    • Louisville, Kentucky, United States, 40291
      • GSK Investigational Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • GSK Investigational Site
    • Fall River, Massachusetts, United States, 02725
      • GSK Investigational Site
    • Methuen, Massachusetts, United States, 01844
      • GSK Investigational Site
    • Roslindale, Massachusetts, United States, 02135
      • GSK Investigational Site
  • Michigan
    • Grosse Pointe Woods, Michigan, United States, 48236
      • GSK Investigational Site
  • Mississippi
    • Biloxi, Mississippi, United States, 39531
      • GSK Investigational Site
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • GSK Investigational Site
  • New York
    • Syracuse, New York, United States, 13210
      • GSK Investigational Site
  • North Carolina
    • Fayetteville, North Carolina, United States, 28304
      • GSK Investigational Site
    • Raleigh, North Carolina, United States, 27612
      • GSK Investigational Site
    • Wilmington, North Carolina, United States, 28401
      • GSK Investigational Site
  • Pennsylvania
    • Cranberry Township, Pennsylvania, United States, 16066
      • GSK Investigational Site
    • Monongahela, Pennsylvania, United States, 15063
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15213
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15217
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15025
      • GSK Investigational Site
  • Rhode Island
    • Warwick, Rhode Island, United States, 02886-6110
      • GSK Investigational Site
  • South Carolina
    • Charleston, South Carolina, United States, 29406
      • GSK Investigational Site
    • Greenville, South Carolina, United States, 29607
      • GSK Investigational Site
  • Texas
    • Austin, Texas, United States, 78745
      • GSK Investigational Site
    • Beaumont, Texas, United States, 77706
      • GSK Investigational Site
    • Carrollton, Texas, United States, 75010
      • GSK Investigational Site
    • Dallas, Texas, United States, 75251
      • GSK Investigational Site
    • Houston, Texas, United States, 77055
      • GSK Investigational Site
    • Katy, Texas, United States, 77450
      • GSK Investigational Site
    • Longview, Texas, United States, 75605
      • GSK Investigational Site
    • Plano, Texas, United States, 75024
      • GSK Investigational Site
    • The Woodlands, Texas, United States, 77381-3527
      • GSK Investigational Site
  • Utah
    • Kaysville, Utah, United States, 84037
      • GSK Investigational Site
    • Layton, Utah, United States, 84041
      • GSK Investigational Site
    • Roy, Utah, United States, 84067
      • GSK Investigational Site
    • Syracuse, Utah, United States, 84075
      • GSK Investigational Site
  • Washington
    • Seattle, Washington, United States, 98105
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 25 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Participants and/or participants' parents/LARs, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits).
2. Written or witnessed/thumb printed informed consent obtained from the participant/participant's parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
3. Written or witnessed/thumb printed informed assent obtained from participants below the legal age of consent prior to performance of any study specific procedure.
4. Previous vaccination with 1 dose of MenACWY vaccine at an age of 10 years or older, with an interval of at least 4 years between the previous MenACWY vaccine and enrollment (informed consent and assent [as applicable]) into this study.
5. A male or female between, and including, 15 and 25 years of age (i.e., 25 years and 364 days) at the time of the first vaccination.
6. Healthy participants as established by medical history, physical examination, and clinical judgment of the investigator before entering into the study.
7. Female participants of non-childbearing potential may be enrolled in the study. Non childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or post-menopause.

8. Female participants of childbearing potential may be enrolled in the study, if the participant:

   • has practiced adequate contraception for 30 days prior to vaccination, and
   • has a negative pregnancy test* on the day of vaccination, and
   • has agreed to continue adequate contraception during the entire intervention period and for 30 days after completion of the vaccination series.

Exclusion Criteria:

1. Current or previous, confirmed or suspected disease caused by N. meningitidis.
2. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrollment.
3. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s)/product.
4. Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM 197) and latex medicinal products or medical equipment whose use is foreseen in this study.
5. Progressive, unstable or uncontrolled clinical conditions
6. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.

7. Abnormal function or modification of the immune system resulting from:

   • Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).
   • Systemic administration of corticosteroids (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days prior to study vaccination until the following post vaccination blood sample. This will mean prednisone ≥20 mg/day (for adult participants and ≥0.5 mg/kg/day with maximum ≥20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.
   • Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
   • Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).
8. Any neuroinflammatory (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures). History of febrile convulsions should not lead to exclusion.
9. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
10. Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study vaccine(s)/product during the period beginning 30 days before the first dose of study vaccine(s)/product (Day -29 to Day 1), or planned use during the study period.
11. Previous vaccination against any group B meningococcal vaccine at any time prior to informed consent and assent as applicable (according to the participant's age).
12. Previous vaccination with 2 or more doses of MenACWY vaccine.
13. Administration/planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before any dose of study vaccine(s)/product until the following post-vaccination blood sample.
14. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to any vaccine/product dose until the following post-vaccination blood sample. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants and ≥0.5 mg/kg/day with maximum ≥20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.
15. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non investigational vaccine/product (drug or medical device).
16. Child in care.
17. Pregnant or lactating female.
18. Female planning to become pregnant or planning to discontinue contraceptive precautions.
19. History of/current chronic alcohol and/or drug abuse.
20. Involvement in the study as a study staff member or being immediate dependents, family, or household member of a study staff member.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ABCWY Group; Participants received 2 doses of the MenABCWY vaccine on Day 1 and Day 181 (0,6-month schedule) and 1 dose of placebo on Day 211.	Combination product: MenABCWY vaccine; 2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.; Combination product: Placebo; 1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
Active Comparator: ACWY Group; Participants received 1 dose of MenACWY vaccine on Day 1 and 2 doses of MenB vaccine on Day 181 and Day 211.	Biological: MenACWY vaccine; 1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group; Other Names: Menveo; Combination product: MenB vaccine; 2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.; Other Names: Bexsero

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline	Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (>=) 16 for participants with a pre-vaccination hSBA titer <4; - a post-vaccination hSBA titer >= 4 times the LLOQ for participants with a pre vaccination hSBA titer >= limit of detection (LOD) but < LLOQ; and - a post-vaccination hSBA titer >= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer >= LLOQ.	At 1 month after vaccination schedule (i.e., Day 211 for ABCWY group and Day 31 for ACWY group) compared to Day 1 (Baseline)
Percentages of Participants With a 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline	Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (>=) 16 for participants with a pre-vaccination hSBA titer <4; - a post-vaccination hSBA titer >= 4 times the LLOQ for participants with a pre vaccination hSBA titer >= limit of detection (LOD) but < LLOQ; and - a post-vaccination hSBA titer >= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer >= LLOQ.	At 1 month after the first vaccination (i.e., Day 31) compared to Day 1 (Baseline)
Number of Participants With Solicited Administration Site Events Following Vaccination at Day 1 for ABCWY Group and ACWY Group	Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.	During the 7 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Number of Participants With Solicited Administration Site Events Following Vaccination at Day 181 for ABCWY Group	Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.	During the 7 days (including day of vaccination) following vaccination at Day 181 for ABCWY group
Number of Participants With Solicited Systemic Events Following Vaccination at Day 1 for the ABCWY Group and ACWY Group	Assessed solicited systemic events include fever [body temperature >= 38.0°C (celsius) /100.4°F (Fahrenheit)], nausea, fatigue, myalgia, arthralgia, headache.	During the 7 days (including day of vaccination) following vaccination at day 1 for the ABCWY group and ACWY group
Number of Participants With Solicited Systemic Events Following Vaccination at Day 181 for the ABCWY Group	Assessed solicited systemic events include fever [body temperature >= 38.0°C/100.4°F], nausea, fatigue, myalgia, arthralgia, headache.	During the 7 days (including day of vaccination) following vaccination at day 181 for the ABCWY group
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)	Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. An MAE is defined as an unsolicited AE for which the participant received medical attention such as hospitalization, or an emergency room visit, or visit to/by a health care provider.	During the 30 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group	Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.	During the 30 days (including day of vaccination) following vaccination at day 181 for ABCWY group
Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs	SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were assessed throughout the study period are reported in this outcome measure.	From Day 1 to Day 361 (throughout the study period)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination	The immune response to MenABCWY vaccine after the first dose and single dose of MenACWY vaccine was evaluated by measuring the percentage of participants with hSBA titers >= LLOQ against each of the serogroups A, C, W and Y.	At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)
Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination	The immune response to MenABCWY vaccine after the second dose was evaluated by measuring the percentage of participants with hSBA titers >= LLOQ against each of the serogroups A, C, W and Y.	1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])
hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination	The immune response to MenABCWY after first dose and single dose of MenACWY vaccine was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.	At Day 1 and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)
hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination	The immune response to MenABCWY after second dose was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.	1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])
Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination	The immune response to MenABCWY vaccine after first and single dose of MenACWY vaccine are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.	At 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group) compared to baseline (Day 1)
Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After Second MenABCWY Vaccination	The immune response to MenABCWY vaccine after second dose are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.	At 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose]) compared to baseline (Day 1)
Percentages of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After the Second Dose of MenABCWY Vaccination	The immune response to MenABCWY vaccine after second dose was evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).	At Day 1 and at Day 211
Percentages of Participants With 4-fold Rise in hSBA Titers Against Each N. Meningitidis Serogroup B Indicator Strains at 1 Month After the Second MenABCWY Vaccination	The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer >=16 for participants with a pre-vaccination hSBA titer <4; . a post-vaccination hSBA titer >= 4 times the LLOQ for participants with a prevaccination hSBA titer >= limit of detection (LOD) but < LLOQ; and, a post-vaccination hSBA titer >= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer >= LLOQ.	At Day 211 compared to baseline (Day 1)
GMTs Against Each Serogroup B Indicator Strains at Day 1 and at 1 Month After Second MenABCWY Vaccination	The immune response to MenABCWY vaccine after the second dose was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination.	At Day 1 and at Day 211
GMRs Against Each Serogroup B Indicator Strains at 1 Month After Second Dose of MenABCWY Vaccination	The immune response to MenABCWY vaccine after second dose was evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.	At Day 211 compared to baseline (Day 1)

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): January 25, 2021
• Primary Completion (Actual): May 3, 2023
• Study Completion (Actual): September 29, 2023

Study Registration Dates

• First Submitted: January 11, 2021
• First Submitted That Met QC Criteria: January 11, 2021
• First Posted (Actual): January 13, 2021

Study Record Updates

• Last Update Posted (Actual): July 3, 2024
• Last Update Submitted That Met QC Criteria: June 7, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: Neisseria meningitidis; Meningococcal disease
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Infections; Central Nervous System Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Meningitis, Bacterial; Central Nervous System Bacterial Infections; Meningococcal Infections; Neisseriaceae Infections; Neuroinflammatory Diseases; Meningitis, Meningococcal; Meningitis; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: 213171; 2019-004982-42 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
• IPD Sharing Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
• IPD Sharing Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes